

# 2024 PSMA CONFERENCE

PSMA PET and RLT: Present and Future

January 18-19, 2024

Co-sponsored Event

UCSF Health

UCLA Health



Prostate Cancer  
Foundation  
Curing Together.

## Conference Organizers



**Thomas A. Hope, MD**  
Professor of Radiology  
UCSF



**Jeremie Calais, MD**  
Associate Professor of  
Nuclear Medicine  
University of California,  
LA



**Johannes Czernin, MD**  
Professor of Nuclear Medicine  
University of California,  
LA


## Distinguished Speakers



**Michael J. Morris, MD**  
Prostate Cancer Section Head  
Memorial Sloan Kettering  
Cancer Center



**Oliver Sartor, MD**  
Director of Radiopharmaceutical  
Clinical Trials, Professor  
Mayo Clinic




**Wolfgang Fendler, MD**  
Department of Nuclear Medicine  
University of Duisburg-Essen and  
German Cancer Consortium (DKTK),  
University Hospital Essen



**Louise Emmett, MD**  
Director of Theranostics and  
Nuclear Medicine, Professor  
St Vincent's Hospital  
Sydney, Australia



**Matthias Eiber, MD, PhD**  
Professor, Department of Nuclear Medicine  
Technische Universität München (TUM),  
Munich, Germany



Q&A

Engage with us on our interactive platform.





| Time                  | DAY 1   | Speaker   |
|-----------------------|---|---|
| 8:00-9:00 AM          | <b>BREAKFAST AND REGISTRATION</b>   |   |
| 9:00-9:05 AM          | Introduction  | Charles J. Ryan, MD – Prostate Cancer Foundation  |
| 9:05-9:20 AM          | PSMA primer: the background   | Robert Flavell, MD, PhD – UCSF  |
| 9:20-9:35 AM          | Do the differences in PET agents matter?  | Wolfgang Fendler, MD – University of Duisburg–Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany |
| 9:35-9:50 AM          | False positives in PSMA PET   | Courtney Lawhn Heath, MD – UCSF   |
| 9:50-10:05 AM         | Panel discussion  | Speaker panel   |
| 10:05-10:20 AM        | ProPSMA versus PreRP – value of the prospective literature                                  | Thomas Hope, MD – UCSF  |
| 10:20-10:35 AM        | Evaluation of the primary tumor with PSMA PET: time impact of the PRIMARY trial             | Louise Emmett, MD – St. Vincent's Hospital Sydney, Australia  |
| 10:35-10:50 AM        | Experience with PSMA-targeted fluorescence guided surgery                                   | Peter Carroll, MD, MPH – UCSF   |
| 10:50-11:05 AM        | Incorporating PSMA PET into RT planning: impact on definitive therapy                       | Nicholas Nickols, MD – UCLA   |
| 11:05-11:20 AM        | Clinical Impact of PSMA PET prior to prostatectomy  | Robert Reiter, MD – UCLA  |
| 11:05-11:20 AM        | Panel discussion  | Speaker panel   |
| <b>11:20-11:40 AM</b> | <b>COFFEE BREAK</b>   |   |
| 11:40-11:55 AM        | Experience with PSMA-targeted fluorescence guided surgery                                   | Peter Carroll, MD, MPH – UCSF   |
| 11:55 AM - 12:10 PM   | Role of MDT in BCR: Oligometastatic disease   | Amar Kishan, MD – UCLA  |
| 12:10-12:25 PM        | Role of PSMA PET in CRPC patients   | Wolfgang Fendler – University of Duisburg–Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany     |
| 12:25-12:40 PM        | Panel discussion  | Speaker panel   |
| 12:40-12:45 PM        | Enhancing access to radiotheranostics for cancer care, worldwide by the Oncidium foundation | Alice Viana, PhD – Oncidium Foundation  |
| 12:45-1:45 PM         | <b>LUNCH BREAK</b>  |   |
| 1:45-2:00 PM          | PSMA PET appropriate use criteria   | Michael Morris, MD – Memorial Sloan Kettering Cancer Center   |
| 2:00-2:15 PM          | PSMA PET standardized reporting   | Matthias Eiber, MD, PhD – Technische Universität München (TUM), Munich, Germany   |
| 2:15-2:30 PM          | Trials evaluating the impact of PSMA PET on management and outcomes                         | Amar Kishan, MD – UCLA  |
| 2:30-3:45 PM          | Tumor Board Discussion (PSMA PET)   |   |
| 3:45-3:50 PM          | Wrap up for the day   | Thomas Hope, MD – UCSF<br>Jeremie Calais, MD, MSc – UCLA<br>Johannes Czernin, MD – UCLA                                     |
| 3:50-4:10 PM          | Poster power pitches  |   |
| 4:10-5:10 PM          | Poster session reception  |   |
| 5:10-5:20 PM          | Poster awards   |   |

| Time                 | DAY 2   | Speaker  |
|----------------------|---|--|
| 7:00-8:00 AM         | <b>BREAKFAST AND REGISTRATION</b>   |  |
| 8:00-8:15 AM         | Treatment Landscape in mCRPC  | Matthew Rettig, MD – UCLA  |
| 8:15-8:30 AM         | PSMA radioligand therapy: the VISION and TheraP trials                                    | Michael Morris, MD – Memorial Sloan Kettering Cancer Center  |
| 8:30-8:45 AM         | PSMA PET selection of patients for PSMA RLT   | Jeremie Calais, MD, MSc – UCLA   |
| 8:45-9:15 AM         | PSMAFore, SPLASH and ECLIPSE: are they different?   | Michael Morris, MD – Memorial Sloan Kettering Cancer Center<br>Oliver Sartor, MD – Mayo Clinic<br>Thomas Hope, MD – UCSF |
| 9:15-9:30 AM         | What is the optimal time for PSMA RLT therapy   | Oliver Sartor, MD – Mayo Clinic  |
| 9:30-9:45 AM         | EnzaP and the role of AR targeted agents  | Louise Emmett, MD – St. Vincent's Hospital Sydney, Australia   |
| 9:45-10:00 AM        | Panel discussion  | Speaker panel  |
| 10:00-10:20 AM       | COFFEE BREAK  |  |
| 10:20-10:35 AM       | Imaging response with PSMA RLT  | Jeremie Calais, MD, MSc – UCLA   |
| 10:35-10:50 AM       | Post-treatment imaging  | Louise Emmett, MD – St. Vincent's Hospital Sydney, Australia   |
| 10:50-11:05 AM       | The role of quantitative dosimetry  | Carlos Uribe, PhD – BC Cancer and The University of British Columbia   |
| 11:05-11:20 AM       | Panel discussion  | Speaker panel  |
| 11:20 AM-12:35 PM    | Tumor Board Discussion (PSMA RLT)   |  |
| <b>12:35-1:35 PM</b> | <b>LUNCH BREAK</b>  |  |
| 1:35-2:10 PM         | Workflow considerations from the front desk to nursing including the supportive care idea | Linda Gardner, MSN, RN, VA-BC – UCLA<br>Amanda Morley, RN, BSN – UCSF  |
| 2:10-2:25 PM         | Panel discussion  | Speaker panel  |
| 2:25-2:40 PM         | Therapy resistance and combination treatment  | Johannes Czernin, MD – UCLA  |
| 2:40-2:55 PM         | Experience with Immunotherapy   | Rahul Aggarwal, MD – UCSF  |
| 2:55-3:10 PM         | New theranostic targets in prostate cancer  | Robert Flavell, MD, PhD - UCSF   |
| 3:10-3:25 PM         | Cocktails/ portfolio of alpha and beta emitters to improve outcomes                       | Matthias Eiber – Technische Universität München (TUM), Munich, Germany   |
| 3:25-3:40 PM         | Role of Ra-223 in the setting of PSMA PET   | Oliver Sartor, MD – Mayo Clinic  |
| 3:40-4:10 PM         | Round Table Discussion: moderated panel   | Speaker panel  |
| 4:10-4:15 PM         | Closing Comments  | Thomas Hope, MD – UCSF<br>Jeremie Calais, MD, MSc – UCLA<br>Johannes Czernin, MD – UCLA                                  |

Special thanks to our sponsors:

Platinum Sponsors



NOVARTIS

Gold Sponsors



LANTHEUS™



Telix

Silver Sponsors



Bronze Sponsors



With contributions from IBA sa

[tiny.ucsf.edu/program](http://tiny.ucsf.edu/program)

